Clinical

Dataset Information

0

Phase II Trial of LBH589 in Refractory Colorectal Cancer

ABSTRACT: The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2056360 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Transcriptomics Phase I/Ii study of mTOR inhibitor everolimus and Hyper-CVAD plus RAD001 (Everolimus) chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
2017-01-01 | GSE60540 | GEO
Unknown Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
| S-EPMC6792497 | biostudies-literature
Transcriptomics Phase I Clinical Trial of ES-285
2009-04-01 | GSE12062 | GEO
Unknown Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer.
| S-EPMC6304301 | biostudies-literature
Transcriptomics Gene expression profiles of 16 relapsed/refractory CLL patients treated with lenalidomide in a phase II clinical trial
2017-10-12 | GSE87910 | GEO
Unknown Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
| S-EPMC2376928 | biostudies-other
Unknown Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
| S-EPMC7216452 | biostudies-literature
Unknown Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
| S-EPMC6663939 | biostudies-literature
Transcriptomics Alanyl-glutamine in peritoneal dialysis fluids - a randomized controlled phase I/II trial
2020-01-24 | GSE57070 | GEO
Unknown A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
| S-EPMC3228156 | biostudies-literature